— Know what they know.
Not Investment Advice

AVEO NASDAQ

AVEO Pharmaceuticals, Inc.
1W: +0.4% 1M: +0.7% 3M: +0.5% 1Y: +300.0% 3Y: +135.8% 5Y: -46.8%
$15.00
Last traded 2023-01-19 — delisted
NASDAQ · Healthcare · Biotechnology

Balance Sheet Trends

Total Assets
$105M +57.4% ▲
5Y CAGR: +31.0%
Total Liabilities
$59M +88.1% ▲
5Y CAGR: +15.3%
Shareholders Equity
$46M +30.0% ▲
Cash & Investments
$71M +14.2% ▲
5Y CAGR: +24.7%
Total Debt
$11K -99.9% ▼
5Y CAGR: -76.1%
Net Debt
-$71M -48.1% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2017FY2018FY2019FY2020FY2021
— Assets —
Cash$15M$24M$30M$62M$71M
Short-Term Investments$19M$0$18M$0$0
Cash & ST Investments$34M$24M$48M$62M$71M
Net Receivables$402K$3M$2M$1M$10M
Inventory$0$0$0$0$2M
Other Current Assets$16M$482K$1M$3M$23M
Total Current Assets$50M$28M$51M$66M$105M
Property, Plant & Equip.$0$0$0$1M$454K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$17M
Other Non-Current Assets$15K$0$0$158K-$17M
Total Non-Current Assets$15K$0$0$1M$605K
Total Assets$50M$28M$51M$67M$105M
— Liabilities —
Accounts Payable$2M$3M$1M$3M$3M
Short-Term Debt$0$3M$10M$1M$11K
Deferred Revenue$395K$2M$2M$2M$578K
Other Current Liabilities$29M$10M$8M$10M$15M
Total Current Liabilities$32M$18M$21M$17M$19M
Long-Term Debt$18M$16M$6M$13M$0
Other Non-Current Liab.$39M$17M$6M$1M$41M
Total Non-Current Liabilities$59M$37M$15M$15M$41M
Total Liabilities$91M$55M$36M$32M$59M
— Equity —
Common Stock$118K$126K$161K$27K$34K
Retained Earnings-$587M-$595M-$586M-$621M-$675M
Accumulated OCI-$4K$1K$0$0-$3K
Total Stockholders Equity-$41M-$27M$15M$35M$46M
Total Liabilities & Equity$50M$28M$51M$67M$105M
— Key Metrics —
Total Debt$37M$19M$16M$14M$11K
Net Debt$22M-$5M-$14M-$48M-$71M
Total Investments$19M$0$18M$0$17M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms